Similarly, in human studies, in which the expression of the ErbB receptors was correlated with the clinical tumor behavior, revealed that ErbB2 was mainly associated with aggressive and/or resistant prolactin-secreting PitNETs [176]. This evidence concerns the gene PRL and neoplasm.